Share Name Share Symbol Market Type Share ISIN Share Description
Shire Plc LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +22.00p +0.69% 3,202.00p 3,208.50p 3,210.50p 3,237.00p 3,179.50p 3,206.50p 3,251,476 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11,224.6 3,149.2 348.7 9.5 29,124.83

Shire (SHP) Latest News (3)

More Shire News
Shire Takeover Rumours

Shire (SHP) Share Charts

1 Year Shire Chart

1 Year Shire Chart

1 Month Shire Chart

1 Month Shire Chart

Intraday Shire Chart

Intraday Shire Chart

Shire (SHP) Discussions and Chat

Shire Forums and Chat

Date Time Title Posts
17/2/201819:51SHIRE Pharmaceuticals836
16/2/201820:11ADDERALL XR sales boost Shire2,356
15/2/201722:25Time to Look at Shire (SHP)-
03/12/201621:04Analysts' Perspective on Shire (SHP)-
29/8/201617:22New Opportunity for Shire (SHP)-

Add a New Thread

Shire (SHP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Shire trades in real-time

Shire (SHP) Top Chat Posts

DateSubject
17/2/2018
08:20
Shire Daily Update: Shire Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SHP. The last closing price for Shire was 3,180p.
Shire Plc has a 4 week average price of 3,034p and a 12 week average price of 3,034p.
The 1 year high share price is 5,067p while the 1 year low share price is currently 3,034p.
There are currently 909,582,311 shares in issue and the average daily traded volume is 4,515,356 shares. The market capitalisation of Shire Plc is £29,124,825,598.22.
15/2/2018
09:38
steeplejack: So let me get this right.When the price goes up,analysts nudge the target price higher and when the price goes lower,they adjust their target prices lower.They follow the share price,they are not forecasting or dictating it or using the tried and tested suggested PE relative.They may as well just select the number they first thought of.
14/2/2018
17:44
philanderer: US outfit Jefferies said its EPS forecasts would require “trimming̶1;, though it maintained its ‘buy’ recommendation and £49 a share price target. “Shire remains something of a contradiction in terms of general market attitude,” said Richard Hunter, head of markets at Interactive Investor. “The shares have lost some 30% over the last year as concerns persist, as compared to a drop of 0.6% for the wider FTSE100. “Despite this underperformance the shares are clearly well regarded as a potential growth story, with the market consensus of the company as a strong buy having been in place for some time.” proactiveinvestors.co.uk
14/2/2018
15:54
romeike: The fact this looks to be ending the day flat suggests the share price is firmly a product of sentiment and external influence right now rather than anything to do with the Company itself.
31/1/2018
18:04
justiceforthemany: For what it's worth here's Zak Mir's latest blog update from yesterday: - Shire (SHP) – waiting, although low share price lessens timeframe of developments. This is because for January there have been more biotech deals done than ever before.
30/11/2017
17:56
justiceforthemany: But even with this plethora of problems, it is hard to see that much downside for the shares. Broker Liberum estimates that even if the entire value of Shire's hemophilia franchise were written off, a fair "risked" net present value (NPV) for the shares would be 3,419p – only 8 per cent below the current price. However, despite Roche’s success, there is still likely to be significant value in the hemophilia business as many existing users are likely to remain loyal. On Liberum's "base case" scenario, which forecasts a 25 per cent decline in non-inhibitor hemophilia sales between 2017 and 2022, the broker puts the risked NPV at 4,228p - 14 per cent above the current share price. Moreover, there are some reasons to be bullish about Shire. Its immunology division (14 per cent of annual product sales) reported 32 per cent revenue growth in the third quarter of 2017 – 18 per cent ahead of consensus forecasts – thanks to strong demand for infection prevention medicine Gammagard. Its oncology franchise is also gathering momentum, and recently launched unique products Mydayis (for attention deficit hyperactivity disorder) and Xiidra (for dry eye syndrome) are also performing well. Meanwhile, self-help offers promise. Cost savings from the integration of Baxalta led to a 3 per cent reduction in general and administration expenses to $27m in the third quarter. And a manufacturing review has identified $100m savings from 2019 with the potential to increase this to $300m by 2023. Manufacture of Cinryze should be bought in-house early next year to address the supply problems. And a strategic review of its neuroscience business could mean a spin-off to help alleviate debt issues. Bringing debt down could prove a major catalyst for the share price. Having peaked at $23.6bn after the Baxalta deal last year, net debt at the end of the third quarter was down to $20.4bn. Liberum expects year-end net debt to be less than three times cash profit at the year-end, at $19bn, a reasonably comfortable 2.2 times cash profits by the end of 2018 and net debt of a very manageable 1.5 times by 2019. This reduction in net debt could drive a serious re-rating of the shares given that, according to Bloomberg data, Shire's current forward earnings multiple of nine is in the bottom one per cent of the 10-year range.
25/10/2017
12:47
philanderer: Credit Suisse Slashes Shire Target Price, Says Discount To Peers "Unjustified" Shire's current discount to its global sector peers is unjustified, even under a worst case scenario for haemophilia and hereditary angiodema, Credit Suisse argues. In a research report published on Wednesday, the analysts said the shares were then trading at a roughly 40% discount in terms of the price-to-earnings multiple, amid suggestions that so-called 'sell-side forecasts are "unrealistic". Yet even after revisiting its own estimates for Xidra, lowering its assumptions for the HAE franchise, assuming faster erosion from competition for Lialda and lowering its haemophilia numbers, it found that the shares should be trading 23% higher. Specifically, the Swiss broker dropped its projections for the company's 2020 revenues and earnings per share by 8% and 15%, pushing their estimate of net asset value from 5590p to 5190p and the target price from 5350p to 4500p. The theoretical upside in the share price as implied by its estimates held true even under worst case scenarios for haemophilia and HAE erosion. Hence, Credit Suisse stuck by its 'outperform' recommendation on the stock. "We conclude that, despite all the recent setbacks and uncertainty, the current valuation effectively eliminates haemophilia, Xiidra & HAE income." HTTPS://uk.webfg.com/news/broker-recommendations/credit-suisse-slashes-shire-target-price-says-discount-to-peers-unjustified--2934095.html
24/10/2017
13:39
steeplejack: This share price performance,we're not far above a three low,makes the Baxalta acquisition look like an error of judgement.On Friday,the management are going to have to make a very good apologia as to why the market is an idiot and why the company is a snip at these prices.First and foremost,analysts will scour the results looking for anything that might vindicate the weakness in the share price.In that context,it's anyone's bet whether the shares slump further or enjoy a sharp recovery.I lost touch with the thinking behind this share when they broke down through £40.
17/10/2017
16:51
justiceforthemany: A dramatic slump again today then wipes out all the gains of yesterday. The only positive is the bigger shareholders are clearly getting very angry and frustrated with the share price here which may trigger some action from the board. [...] Sachem Head Capital Management reportedly wants Shire to offload or spin-off some of its assets as it grows frustrated with the falling share price
21/9/2017
17:51
justiceforthemany: As I said before the CEO gave a long interview with the FT a couple of months ago about how 'fed up' he was with the share price and how he felt the market was undervaluing the company. At the time the share price was 4400p. The share price is now 3800p and has been down to 3600p. Competition concerns are vague and unsubstantiated at the moment - only those 'in the know' truly know what is going on behind the scenes. Brokers continue to target as high as 6000p - they are pretty hopeless but this is a huge disparity with the current share price I guess this is what they feel Shire would be worth if someone bid. If he really is as fed up as he seems I doubt he would turn down an offer around 5000p this time. As for GBP vs USD funny how Shire gets hammered more than its peers who also have large earnings in USD.
06/9/2017
18:03
justiceforthemany: 5.09c/share so based on today's exchange rate = 3.9p/share Looking ahead and what is a fair share price here? I know brokers have been in the 6000p range which seems a way off at the moment. However based on EPS of $5/share and the current exchange rate you can see where they are getting this target from. AZN and GSK both trade on P/E's around 15. GSK is hardly a 'growth' share. Merck, Novartis & Co trade in the high 20's. Being negative lets say EPS next year falls 10% due to 'competition' and the £ strengthens (unlikely) so $1.35 = £1 Even then on a P/E of 15 the share price should be 5000p+
Shire share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180217 23:28:35